Axinn partner Stacie Ropka moderated a panel at the 2017 World Biosimilar Congress USA in San Diego. During "The Value of Certainty in the Biosimilar Regulatory Environment: Informed Thinking on Global Regulations and the IP Environment," panelists discussed which BPCIA uncertainties are causing the greatest hurdles; what we can expect in the next one to two years; whether the EMA and FDA are aligned in their thinking; how the ongoing patent dance litigation will help or hurt entry into the market and if a Supreme Court ruling will sort everything out.